PACB•globenewswire•
PacBio Completes Sale of Short-Read Sequencing Assets
Summary
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 2, 2026 by globenewswire